Theriva Biologics Commences First Patient Dose in VIRAGE2 Phase 2a Trial for Metastatic Pancreatic Ductal Adenocarcinoma

Theriva Biologics, Inc. (NYSE American: TOVX) announced on August 6, 2026 that it has administered the first dose of its investigational agent, VCN‑01 (zabilugene almadenorepvec), to a patient participating in the VIRAGE2 Phase 2a clinical trial. The study, described as a small, proof‑of‑concept investigation, aims to evaluate more frequent repeated dosing of VCN‑01 in patients with first‑line metastatic pancreatic ductal adenocarcinoma (PDAC) who are receiving standard‑of‑care gemcitabine/nab‑paclitaxel chemotherapy.

Strategic Rationale

The VIRAGE2 study builds on encouraging safety and efficacy signals observed in the preceding VIRAGE Phase 2b trial. Regulatory feedback from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) has underscored the potential of repeated VCN‑01 administration to deliver clinical benefit in this hard‑to‑treat malignancy. By refining the dosing regimen in a controlled Phase 2a setting, Theriva intends to lay the groundwork for a future Phase 3 pivotal trial that could solidify the therapeutic value of its adenovirus‑based platform.

Company Context

Theriva Biologics specializes in an adenovirus platform engineered for intravenous, intravitreal, and antitumoral delivery. The platform’s mechanism is designed to induce tumor cell death, enhance the penetration of co‑administered cancer therapies, and stimulate a durable anti‑tumor immune response. The company is headquartered in Rockville, Maryland, and has been trading on the NYSE American since its IPO on June 26, 2006.

As of the most recent trading session on August 4, 2026, TOVX shares closed at $0.2251. The company’s market capitalization stands at approximately $9.6 million, with a price‑to‑earnings ratio of ‑0.2 and a beta of 1.11. The 52‑week trading range has spanned from $0.16 to $0.86, reflecting the volatility typical of early‑stage biopharmaceutical firms.

Recent Market Activity

On August 6, 2026, the stock experienced a modest decline of 1.4 %, trading as low as $0.2250 and closing at $0.2251. Trading volume fell 67 % below the 20‑day average, with roughly 209,000 shares changing hands. The company’s last quarterly earnings report, released on May 5, 2026, recorded an earnings per share of ($0.05) against quarterly revenue of $0.30 million. Despite these challenges, institutional interest remains evident; Geode Capital Management has recently increased its holdings in TOVX shares.

Outlook

The successful initiation of the VIRAGE2 trial represents a critical milestone for Theriva Biologics. Should the study confirm the safety and preliminary efficacy of a more frequent VCN‑01 dosing schedule, the company will be well positioned to pursue a larger, confirmatory Phase 3 program. Investors and stakeholders will be closely monitoring interim safety data, enrollment progress, and any subsequent regulatory interactions that could shape the company’s trajectory in the competitive oncology therapeutics landscape.